What is Pharmaceutical Continuous Manufacturing?
Continuous pharmaceutical manufacturing proceed for drug developments and API manufacturing. This continuous manufacturing process starts from the processing of basic ingredients to the final product with no need to stop during production. It is mean that there no need to shut down or stop the equipment’s thus, drug is created in zero down time. Continuous manufacturing is also known as Process Manufacturing which operates 24/7. The main aim of the continuous manufacturing flow is to manufacture or process materials on continuous basis. This manufacturing is more time-efficient, which decreases energy requirements and surge productivity. This all benefits of continuous pharmaceutical manufacturing reduces overall waste and cost of production. Further, it reduces risk of human error as few people are involved in continuous processing from start to finish. In pharmaceutical industry, Continuous manufacturing gaining new approach for the production of oral solid dosage (OSD) to fulfil the industry’s demands for rapid product development. Industry demands for higher yields with least waste and human error. Thus continuous pharmaceutical manufacturing is more efficient than batch production. In addition, governments and regulatory bodies are progressively supporting for continuous manufacturing owing its unique feature. In December 2016, The United States passed the 21st Century Cures Act, which promoted advanced pharmaceutical manufacturing which has led much of the drive for continuous manufacturing and also provided funding of USD 4.9 million to support the use of continuous manufacturing techniques for pharmaceuticals.
The market study is broken down by Type (Integrated Systems and End to End Systems), by Application (API manufacturing and Final Drug Development) and major geographies with country level break-up.
There are various companies are operating in the market to provide continue pharmaceutical manufacturing. Increased demand for industrial use is impacting on the demand for continue pharmaceutical manufacturing in positive manner. Hence to grab the opportunity associated with the market, many new market players are entering to the market. The market leaders are investing on organic and non-organic strategic growth initiatives to become dominant in this industry.
Korsch AG (Germany), GEA Group AG (Germany), Siemens AG (Germany), Thermo Fisher Scientific Inc. (United States), Corning Life Sciences(United States), Coperion GmbH (Germany), Gebrüder Lödige Maschinenbau GmbH (Germany), Scott Equipment Company (United States), Baker Perkins Ltd. (United Kingdom), S K Biotek ltd (United States) and Sturtevant, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Continuus Pharmaceutical (United States) and Glatt GmbH (Germany).
AdvanceMarketAnalytics has segmented the market of Global Pharmaceutical Continuous Manufacturing market by Type, Application and Region.
On the basis of geography, the market of Pharmaceutical Continuous Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Pharmaceutical Companies will boost the Pharmaceutical Continuous Manufacturing market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
In March 2021, Emerson has established partnership with IMA Active. IMA Active is a manufacturer of solid dose processing. This partnership is mainly for developing new solutions to control continuous manufacturing of oral solid dose pharmaceuticals. Further, it will focus on making easier to adopt continuous manufacturing by improving the quality, quantity and efficiency of production.
- Augmented Pharmaceutical Industry Expenditure
- Continuous Pharmaceutical Manufacturing Reduces Manufacturing Costs for Long Term Hence It Is Mostly Preferred
- Reduces the Risk of Human Error & Improves Quality Drives the Demand For the Continue Pharmaceutical Manufacturing
- Technological Advancements Is Continuous Manufacturing Process Is Providing Opportunity for Quicker and Errorless Drug Production
- Limitations for Small Scale Pharmaceutical Companies
- High Capital Investments to Install Production Lines
Key Target AudienceVenture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Pharmaceutical Companies, Government Regulatory, Research Organizations and End-Use Industries
About ApproachDuring this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase